Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Uprosertib in BRAF Wild-type Melanoma
NCT01941927Phase 2Completed
- Start
- Sep 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of uprosertib in melanoma. Primary endpoint: Objective Response Rate up to 2 years. Started Sep 2013; status: completed.
02
Drugs
uprosertib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01941927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01941927.